Overview

A Phase I Study of BR108 in Hematological Malignancies

Status:
TERMINATED
Trial end date:
2024-06-21
Target enrollment:
Participant gender:
Summary
A Phase I study of BR108 in hematological malignancies
Phase:
PHASE1
Details
Lead Sponsor:
BioRay Pharmaceutical Co., Ltd.